merged_eli-lilly-zepbound-price.txt


<question_number>1</question_number>
<answer>Positioning vials as a safer alternative to compounded drugs despite higher price than some compounded versions</answer>
<question_number>2</question_number>
<answer>By offering a direct-to-consumer platform (LillyDirect) with lower-priced vials, bypassing telehealth companies that rely on compounded drugs</answer>
<question_number>3</question_number>
<answer>Compounded drugs are subject to less oversight, posing risks to safety, quality, and effectiveness</answer>
<question_number>4</question_number>
<answer>To undercut compounded drugs by offering a safer, lower-priced option to regain customers</answer>
<question_number>5</question_number>
<answer>The FDA's shortage list status allows compounding pharmacies to legally produce tirzepatide; removing it would eliminate competition</answer>
<question_number>6</question_number>
<answer>Direct-to-consumer sales bypassing intermediaries to ensure transparent pricing</answer>
<question_number>7</question_number>
<answer>Potential increased use of Lilly's vials by Medicare beneficiaries despite risks for older adults</answer>
<question_number>8</question_number>
<answer>Patients may perceive compounded drugs as less safe due to Lilly's emphasis on vial safety</answer>
<question_number>9</question_number>
<answer>Being listed on the FDA's shortage list</answer>
<question_number>10</question_number>
<answer>Offering lower-priced vials to compete with compounded drugs and reclaim market share</answer>